NASDAQ:DMAC

Diamedica Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy DMAC

*Your capital is at risk

$5.65

-0.120 (-2.08%)

At Close: Jun 03, 2026

DiaMedica Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 22.08M and sold 0 DMAC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	22.08M shares
● Sell	0 shares
100% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2025 Buy	Stock Option (right to buy) A-Award	Parsons James T. Director	Director	40 739 Value: $167.4K
Jun 01, 2025 Buy	Stock Option (right to buy) A-Award	Pauls Dietrich John President & CEO	CEO / President	600 000 Value: $2.47M
Jun 01, 2025 Buy	Stock Option (right to buy) A-Award	Semba Charles Pauling Director	Director	32 162 Value: $132.2K
Jun 01, 2025 Buy	Stock Option (right to buy) A-Award	Wambeke David J. Chief Business Officer	Officer	250 000 Value: $1.03M
Apr 07, 2025 Buy	Voting Common Shares, no par value per share M-Exempt	Pilnik Richard D. Director	Director	24 000 Value: $50.6K
Apr 07, 2025 Buy	Stock Option (right to buy) M-Exempt	Pilnik Richard D. Director	Director	24 000 Value: $50.6K
Apr 07, 2025 Buy	Stock Option (right to buy) M-Exempt	Pilnik Richard D. Director	Director	24 000 Value: $50.6K
Apr 07, 2025 Buy	Voting Common Shares, no par value per share M-Exempt	Pilnik Richard D. Director	Director	24 000 Value: $50.6K
Feb 20, 2025 Buy	Stock Option (right to buy) A-Award	O'connor Daniel J. Director	Director	64 242 Value: $424.6K
Feb 20, 2025 Buy	Common Stock J-Other	O'connor Daniel J.	Director	0 Value: $0
Feb 20, 2025 Buy	Common Stock J-Other	O'connor Daniel J.	Director	0 Value: $0
Feb 20, 2025 Buy	Stock Option (right to buy) A-Award	O'connor Daniel J. Director	Director	64 242 Value: $424.6K
Feb 13, 2025 Buy	Voting Common Shares, no par value per share M-Exempt	Giuffre Randall Michael Director	Director	5 000 Value: $18.3K
Feb 13, 2025 Buy	Voting Common Shares, no par value per share M-Exempt	Giuffre Randall Michael Director	Director	12 000 Value: $25.3K
Feb 13, 2025 Buy	Stock Option (right to buy) M-Exempt	Giuffre Randall Michael Director	Director	12 000 Value: $25.3K
Feb 13, 2025 Buy	Stock Option (right to buy) M-Exempt	Giuffre Randall Michael Director	Director	5 000 Value: $18.3K
Feb 13, 2025 Buy	Stock Option (right to buy) M-Exempt	Giuffre Randall Michael Director	Director	5 000 Value: $18.3K
Feb 13, 2025 Buy	Stock Option (right to buy) M-Exempt	Giuffre Randall Michael Director	Director	12 000 Value: $25.3K
Feb 13, 2025 Buy	Voting Common Shares, no par value per share M-Exempt	Giuffre Randall Michael Director	Director	12 000 Value: $25.3K
Feb 13, 2025 Buy	Voting Common Shares, no par value per share M-Exempt	Giuffre Randall Michael Director	Director	5 000 Value: $18.3K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Parsons James T. Director	Director	15 917 Value: $85.0K
Jan 02, 2025 Buy	Stock Option (right to buy) A-Award	Parsons James T. Director	Director	4 287 Value: $23.6K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Giuffre Randall Michael Director	Director	10 861 Value: $58.0K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Kuntz Richard Director	Director	9 925 Value: $53.0K
Jan 02, 2025 Buy	Voting Common Shares, no par value per share A-Award	Pilnik Richard D. Director	Director	10 393 Value: $55.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DIAMEDICA THERAPEUTICS INC.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...

Read Full Profile Here